San Diego-based AnaptysBio, Inc. is a clinical-stage biotechnology firm focused on delivering immunology therapeutics. The company's product portfolio includes Imsidolimab, an antibody that inhibits the interleukin-36 receptor currently in Phase 3 trials for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. The company has entered into a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb, as well as license agreements with United Kingdom Research and Innovation and Millipore Corporation. AnaptysBio was previously known as Anaptys Biosciences, Inc. and changed its name in July 2006.